New Molecularly Targeted Therapeutic Approved by FDA for Numerous Blood Disorders
At the end of last week, the U.S. Food and Drug Administration (FDA) announced the approval of the first...
Author:
Karen Honey, PhD
At the end of last week, the U.S. Food and Drug Administration (FDA) announced the approval of the first...
Members of the AACR Project GENIE consortium presented their first analyses of the data during the Pan-Cancer Genomic Analysis...
On Thursday, the U.S. Food and Drug Administration (FDA) expanded the use of the antiangiogenic therapeutic regorafenib (Stivarga) to...
On March 23, the U.S. Food and Drug Administration announced the first-ever approval of a treatment for patients with...
Identifying ways to increase the proportion of patients with melanoma who have clinically meaningful and durable responses to immune...
Earlier this week, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic niraparib (Zejula) for the...
The U.S. Food and Drug Administration (FDA) has approved expanding the use of the immunotherapeutic pembrolizumab (Keytruda) to include...
Earlier this week, the U.S. Food and Drug Administration approved the molecularly targeted therapeutic ribociclib (Kisqali) for use in...
The AACR has a robust program of educational workshops designed to equip early-career investigators with the knowledge, skills, and...
The AACR Annual Meeting, to be held in Washington, D.C., April 1-5, will showcase the best cancer science and...